Literature DB >> 2274637

Plasma HVA in psychiatric patients: longitudinal studies.

J I Javaid1, R P Sharma, P G Janicak, J M Davis.   

Abstract

Plasma homovanillic acid (pHVA) was measured in 40 inpatients (25 schizophrenic and 15 nonschizophrenic patients) who underwent up to 3 weeks of drug washout. Schizophrenic patients were then treated with trifluoperazine for 4 weeks, and weekly behavioral and pHVA measures were obtained. The baseline pHVA had no relationship to age, sex, washout period, diagnosis, or behavioral rating scores. In schizophrenic patients, the baseline pHVA did not differ significantly from any value obtained during 4 weeks of treatment. Although there was significant improvement in clinical symptoms, this was not related to changes in pHVA. Further, changes in any of the four Brief Psychiatric Rating Scale (BPRS) factors (i.e., positive symptoms, negative symptoms, hostility/suspicion, or anxiety/depression) were not correlated with changes in pHVA. Although other studies have reported a positive correlation between pHVA and psychotic symptoms, results of this study suggest that any observed relationship between pHVA and psychosis must be carefully interpreted.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2274637

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  2 in total

1.  Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.

Authors:  B M Cohen; T Tsuneizumi; R J Baldessarini; A Campbell; S M Babb
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion.

Authors:  Tanja Veselinović; Ingo Vernaleken; Paul Cumming; Uwe Henning; Lina Winkler; Peter Kaleta; Michael Paulzen; Christian Luckhaus; Gerhard Gründer
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-27       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.